Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine

Fausto Baldanti, Stefania Paolucci, Giovanni Maga, Nazzarena Labo, Ulrich Hübscher, Alexander Y. Skoblov, Lyubov Victorova, Silvio Spadari, Lorenzo Minoli, Giuseppe Gerna

Research output: Contribution to journalArticlepeer-review

Abstract

Stavudine administration did not increase the frequency of Y181I/C reverse transcriptase (RT) mutations in non-nucleoside reverse transcriptase inhibitor (NNRTI)-treated patients. However, recombinant Y181C HIV-1 showed reduced stavudine susceptibility with respect to both recombinant wild-type and K103N HIV-1 strains. In addition, recombinant Y181I RT enzyme showed reduced susceptibility to stavudine with respect to both wild-type and K103N RT. A previously unnoticed role of Y181I/C RT changes selected by nevirapine or other NNRTI in determining stavudine resistance is documented.

Original languageEnglish
Pages (from-to)1568-1570
Number of pages3
JournalAIDS (London, England)
Volume17
Issue number10
DOIs
Publication statusPublished - Jul 4 2003

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine'. Together they form a unique fingerprint.

Cite this